RxDoctor Payments Data

Jennifer Cunningham, MD

Endocrinology, Diabetes & Metabolism · Green Bay, WINPI 1790771962

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 75.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $11,618 and has fallen 98.8% since, to $141 in 2025.

$15,334in general payments, 2019–2025

Across 28 payments — averaging $547.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$12K
  • Dexcom, Inc.$3K
  • Tandem Diabetes Care, Inc.$205
  • Ascendis Pharma Endocrinology Inc$124
  • Companion Medical, Inc.$112
  • Sun Pharmaceutical Industries Inc.$85
  • plus $69 from 4 others

What the payments were for

  • Consulting fees$7,08846%
  • Speaking & faculty fees$6,01639%
  • Travel & lodging$1,2928%
  • Food & beverage$7825%
  • Education$1571%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,334 in reported general payments places this provider in the 85th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.

See all endocrinology, diabetes & metabolism providers in Wisconsin

Medicare billing

Part B allowed, 2024
$24,544
Medicare patients
93
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide20$26,819
JardianceEmpagliflozin25$25,797
MounjaroTirzepatide18$18,928
Cinacalcet Hcl29$8,178
Humalog Kwikpen U-100Insulin Lispro14$6,110
SynthroidLevothyroxine Sodium31$3,554
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,822
Levothyroxine Sodium175$2,057
Testosterone12$1,854
Hydrocortisone51$1,782
Testosterone Cypionate24$1,001
Methimazole80$933
Calcitriol23$357
Fludrocortisone Acetate13$214
Alendronate Sodium47$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$21$45,74738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.

Other endocrinology, diabetes & metabolism in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →